STOCK TITAN

Dyne Therapeutics Inc - DYN STOCK NEWS

Welcome to our dedicated news page for Dyne Therapeutics (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyne Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyne Therapeutics's position in the market.

Rhea-AI Summary
Dyne Therapeutics, Inc. granted an inducement equity award to its new President and CEO, John G. Cox. The award consists of a non-statutory stock option to purchase up to 679,853 shares of the company's common stock at $26.06 per share. The option has a ten-year term and will vest over four years, subject to Mr. Cox's continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that key executives will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium. The event will be live-streamed and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
conferences
-
Rhea-AI Summary
Dyne Therapeutics appoints John Cox as President and CEO, a seasoned industry leader with global rare disease commercialization experience. Mr. Cox aims to leverage the FORCE™ platform for innovative therapeutics. Former CEO Joshua Brumm steps down to pursue healthcare investing, ensuring a smooth transition. Dyne looks forward to advancing clinical programs and pipeline under Mr. Cox's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
none
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) is set to participate in a fireside chat at Stifel 2024 Virtual CNS Days on March 20, 2024. The company focuses on developing therapeutics for genetically driven diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
conferences
-
Rhea-AI Summary
Dyne Therapeutics, Inc. reports positive clinical data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients, validating the FORCE™ Platform. The company strengthened its balance sheet with a $345 million public offering, extending cash runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.64%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. announces presentations at MDA Conference showcasing initial data from DM1 and DMD programs. The data validates the FORCE™ Platform's promise and targeted muscle delivery. Additional data from ACHIEVE and DELIVER trials expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences clinical trial
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced their participation in two investor conferences in February, including the Guggenheim Healthcare Talks and Oppenheimer Healthcare Life Sciences Conference. The company will present a live webcast of each presentation, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
conferences
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the closing of its underwritten public offering of 19,722,500 shares of its common stock at a public offering price of $17.50 per share, resulting in gross proceeds of approximately $345.1 million. The offering was made by means of a prospectus supplement and accompanying prospectus that form a part of the registration statements. The company's focus on advancing innovative life-transforming therapeutics for genetically driven diseases is evident from this announcement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that Joshua Brumm, president and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The live webcast will be available on the company's website, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
conferences
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. The gross proceeds to Dyne from the offering are expected to be approximately $300.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
Dyne Therapeutics Inc

Nasdaq:DYN

DYN Rankings

DYN Stock Data

2.23B
52.67M
0.91%
86.03%
9.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About DYN

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.